Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (August 2023)
13 slides from Staar Surgical's investor presentation, Aug 9, 2023
Slide 1: STAAR Surgical Investor Presentation August 2023
Exhibit 99.1 Investor Presentation STAAR Surgical | NASDAQ: STAA August 2023
Slide 2: Forward Looking Statements
Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospects for achieving such
Slide 3: Who is STAAR?
Who is STAAR? STAAR develops, manufactures and markets premium implantable lenses for patients seeking Visual Freedom independent of contact lenses and glasses. Our goal is to create a lens-based future for refractive vision correction with EVO ICL as the first choice for doctors and patients IT IS
Slide 4: What is EVO ICL?
What is EVO ICL? • Proprietary lens designed to correct or reduce refractive error (blurred vision), i.e., myopia • EVO ICL is well-positioned as dominant lens-based refractive solution Negligible Lens- 1 A Quick Procedure Advantages Based Competition Eye drops to dilate pupil No Capital Investment
Slide 5: EVO ICL Technology Works
EVO ICL Technology Works HAPPY 2 Million+ 99.4% 1 PATIENTS ICLs Sold Globally of EVO patients surveyed 1 would choose EVO again Safety and Effectiveness 200+ 32% ICL Clinical Papers 200/629 eyes in U.S. EVO FDA study had 2, 3 -3D to -6D SE. 1% 2-3% U.S. MDR rate on FDA MAUDE database (past six Globa
Slide 6: Large Market Opportunity
Large Market Opportunity 5.0 Billion Estimated Myopes in 2050 * 2.0 Billion Today * 6.0 Million Contact Lens Wearers Dropout Annually** * BHVI, adapted from Holden et al. 2016 Ophthalmology. ** Company estimates for U.S. only as of April 13, 2023. 06
Slide 7: Favorable Economics for Refractive Surgeons
Favorable Economics for Refractive Surgeons Surgeon/Clinic Profit Contribution Comparison OBS ASC Surgical Setting Laser Vision Correction Procedure (LVC) $4,700 $8,700 $8,700 Bilateral Patient Price * ($1000) ($2,000) ($2,000) Cost Assumption (Lens or Laser) ** Bilateral ASC Fee $0 $0 ($1,800) Prof
Slide 8: Global Footprint
Global Footprint Direct Hybrid United States China Approved to Sell in Canada S. Korea 75+ Countries U.K. India Germany France OUS Sales > 90% Spain Benelux Japan Italy Singapore Note: Not all distributor markets shown above, e.g., South America and Africa. 08
Slide 9: Why Invest in STAAR?
Why Invest in STAAR?
Slide 10: 2Q23 Results and Outlook
2Q23 Results and Outlook Second Quarter 2023 FY23 Outlook REPORTED AUGUST 2, 2023 ISSUED AUGUST 2, 2023 Reported Record ICL Sales ICL Sales outlook range of $320 million of $93.1 Million +19% Y/Y; 19% to $325 million, which represents 20% +20% Y/Y in Constant growth Y/Y at the midpoint Currency Expe
Slide 11: Sales Growth + Prudent Investment = Leverageable Business Model
Sales Growth + Prudent Investment = Leverageable Business Model Attractive Margins, Earnings and Cash Gross Margin Operating Margin Balance Sheet Cash $ Millions at Year End $226 $200 78.5% 77.5% 15.4% 14.5% 74.5% 73.8% $153 72.4% $120 $104 7.9% 5.3% 4.1% 2018 2019 2020 2021 2022 2018 2019 2020 2021
Slide 12: Making EVO ICL The Global Standard of Care
Making EVO ICL The Global Standard of Care… Happy Customers + Projects and Investments to Accelerate EVO Adoption 1 Happy Surgeon Customers High Performance Management Projects and Investments to Accelerate EVO Adoption… Increase surgeon confidence & training 100% U.S. Surgeon Satisfaction Simplify
Slide 13: STAAR Surgical Investor Meeting New York - Thank you
STAAR Surgical Investor Meeting New York | September 14, 2023 Thank you